Biogen, Proteostasis forge $200M preclinical Alzheimer's pact; New drug class to combat childhood cancer IDed;

Neurodegenerative disorders

> Biogen Idec ($BIIB) has struck a $200M preclinical Alzheimer's drug deal with Proteostasis. Story

> A trial in the U.K has just launched to study the potential of a diabetes drug in slowing the effects of Alzheimer's in patients. Story

Cancer

> Using gene sequencing, a team at St. Jude's Research Hospital has identified a new class of drugs that could be used to treat a type of childhood tumor. Release

Autoimmune diseases

> Scientists at The Johns Hopkins University have discovered that cancer may cause some cases of scleroderma. Release

> Researchers from Sanford-Burnham Medical Research Institute have found a new target to treat psoriasis. Abstract